The decree will enter into force from the second half of November.Continue reading
Ceva-Phylaxia is building a new vaccine factory in Monor (central Hungary) with an investment of HUF 30 billion (EUR 75 million), the foundation stone of which was laid on Thursday.
The plant will start operations at the end of 2026, initially creating 60 new jobs, and by 2029, 120 new jobs, according to the company, which currently employs 1,300 people in Hungary.
The plant will produce fermentation-based, multi-component inactivated vaccines for animals in order to prevent infectious diseases, producing more than 80 billion doses of vaccines annually.
“Ceva-Phylaxia, a subsidiary of the global animal health group Ceva Animal Health, with products in 110 countries, has centuries-old roots in Hungary and is a leading player in the production of animal health vaccines not only in Hungary but also internationally, which it will further strengthen with this investment,” the company highlighted.
Laying the foundation stone of the new plant. Photo: Facebook/Ceva Phylaxia Campus
With the addition of the Monor site, the company will now produce more than 80 billion doses of vaccines annually in six production units in Hungary,
including products that are either produced exclusively in Hungary or produced in the largest quantities in the world.
The development of the company, a strategic partner of the government, will be made possible thanks to a HUF 8.3 billion (EUR 20.4 million) state grant from Hungarian Investment Promotion Agency (HIPA).
“The Ceva Group has made a long-term commitment to Hungary and attaches great importance to the high value and high performance work being carried out at Ceva-Phylaxia. Nothing is more proof of this than today’s announcement of the construction of the new plant. It is primarily thanks to the outstanding expertise and dedication of my colleagues that our company is becoming an increasingly dominant player in the field of animal health in Hungary and abroad,” the statement quoted Tamás Szamkó, CEO of Ceva-Phylaxia, as saying.
Ceva is the 5th largest global animal health company in the world, with 7,000 employees in 47 countries.
In 2023, its turnover reached EUR 1.6 billion.
Its five production units in Hungary produce more than 70 billion doses of vaccines annually to prevent 25 major infectious diseases. According to public company data, in 2023 it had sales of HUF 59.9 billion (EUR 147.3 million), of which HUF 47 billion (EUR 115.6 million) came from exports. A year earlier, exports accounted for almost HUF 43.3 billion (EUR 106.5 million) of the HUF 48 billion (EUR 118 million) total revenue. The company, with equity of HUF 17 billion (EUR 41.8 million), posted an after-tax loss of HUF 3 billion (EUR 7.3 million) last year and HUF 3.8 billion (EUR 9.3 million) the year before.
Via MTI; Featured image via Pexels